Our Platform

Satellite Bio is the first company to establish proprietary protocols that allow us to effectively isolate, expand and mature primary hepatocyte cells in-house. This cutting-edge process yields mature cells capable of effective engraftment and functions as primary hepatocytes in vivo.

From a single liver, we can produce enough Tissue Therapeutics to potentially treat a thousand individuals with advanced liver disease.

We’ve pioneered the creation of Tissue Seeds, which are heterocellular units comprised of our expanded hepatocytes and supportive cells. This precise blend enables optimal engraftment and function. By engineering this microenvironment, our Tissue Seeds ensure the survival and functionality of the transplanted cells, as validated across various animal models.

Our team of experts has optimized the engineering and production of Tissue Therapeutics, transitioning from a labor-intensive academic pursuit to a scalable, enclosed, semi-automated, cost-effective and cGMP-compliant process that produces a stable, cryopreesrved tissue seed and drug product. This approach enables a far-reaching distribution of the stable drug product from a censtralized manufacturing facility. Satellite Bio’s products are truly off-the-shelf advanced therapies. 

Key achievements include:

-Liver isolation

-Cell expansion

-Analytics assays

-Cryopreservation methods